Screener
Eli Lilly LLY Cardiometabolic Health — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:40 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000059478-26-000081
| Line item | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Outside U.S. | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Outside U.S. | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|
| Jardiance(2) | 616 | 615 | 1,232 | 382 | 308 | 690 |
| Trulicity | 908 | 312 | 1,219 | 744 | 348 | 1,092 |
| Other cardiometabolic health | 554 | 477 | 1,031 | 556 | 425 | 980 |
| Total cardiometabolic health | 11,742 | 6,611 | 18,353 | 8,363 | 2,980 | 11,343 |
| Oncology: | ||||||
| Verzenio | 845 | 629 | 1,474 | 929 | 560 | 1,489 |
| Other oncology | 628 | 468 | 1,096 | 490 | 434 | 924 |
| Total oncology | 1,473 | 1,097 | 2,570 | 1,419 | 994 | 2,414 |
Item 1. Financial Statements
FAQ
- What is Eli Lilly's cardiometabolic health — revenue?
- Eli Lilly (LLY) reported cardiometabolic health — revenue of $18.35B in Q2 2026.
- How has Eli Lilly's cardiometabolic health — revenue changed year-over-year?
- Eli Lilly's cardiometabolic health — revenue increased by 61.8% year-over-year, from $11.34B to $18.35B.
- What is the long-term trend for Eli Lilly's cardiometabolic health — revenue?
- Over 3 years (2022 to 2025), Eli Lilly's cardiometabolic health — revenue has grown at a 49.4% compound annual growth rate (CAGR), from $14.46B to $48.22B.
- What does cardiometabolic health — revenue mean?
- This metric represents the total gross sales generated from pharmaceutical products specifically indicated for the treatment of diabetes, obesity, and related cardiovascular and metabolic conditions. It captures the market performance of key therapeutic assets within the company's cardiometabolic portfolio, reflecting both volume growth and pricing dynamics in these high-demand therapeutic areas. This revenue stream is a primary driver of the company's top-line growth and reflects its competitive positioning in the global metabolic disease market.
Ask your AI about Eli Lilly's cardiometabolic health — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude